|Touching BACE. How Inhibiting β-Amyloid Production by Steric Hindrance with a Novel Immunotherapy Improves Memory in PDAPP Mice|
Charles Evans1, 2, Rhian Thomas1, Emma Kidd1, Mark Good2
The work presented in this poster aims to assess whether intracerebroventricular (ICV) administration of 2B3 alleviated age dependent memory deficits in PDAPP mice and to determine whether 2B3 altered APP metabolism and NMDA receptor phosphorylation ex vivo.
|Multiplexed Cell- and Bead-based Assays in a No-wash Format for Biologics Screening and Characterization|
David Onley, Lucy Chammas, Diana Caracino and Paul G. Wylie
Here we present the results generated from multiplexed no-wash protocols using TTP Labtech’s mirrorball, a laser scanning cytometer.
|Development of a Homogenous RSV Neutralization Assay on the Mirrorball Fluorescence Cytometer: A Simple, Safe and Robust Approach for High-throughput Screening|
Anne F. Hammerstein and Lucy Chammas
Here we present the development and implementation of a simple RSV-neutralization assay on TTP Labtech’s mirrorball fluorescence cytometer.
|Super-resolution single molecule localization microscopy of the exocytotic machinery underlying insulin secretion.|
Deirdre M. Kavanagh, Alison Dun, Rory R. Duncan, and Colin Rickman.
Single molecule imaging of the tSNARE proteins involved in insulin secretion.
|Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets|
Zhi-jie Jey Cheng, Jamison Grailer, Pete Stecha, Jun Wang, Jim Hartnett, Frank Fan, and Mei Cong
Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.
|Deep Phenotyping - Harnessing Data Richness for Unsupervised High-Content Analysis|
Huang Dong, Wang Yi, Maciej Hermanowicz, Ke Yiping, Maja Choma, Lee Kee Khoon, Frederic Bard
Recognising the key challenges, we develop an end-to-end computational framework for HCA dubbed “Deep Phenotyping” that perform unsupervised analysis to leverage on the data richness for the discovery of unknown sub-phenotypes with minimal labeling cost.
|Translational Research of oral Neural Crest-Derived Stem Cells (oNCSCs) in Regenerative Dentistry|
Grimm W.-D1,2,4, S. N. Alekseenko9, D. V. Bobryshev1, W. Duncan11, B. Giesenhagen3, E. Gubareva9, Sema S. Hakki6, O.V. Pershina7, I. Schau4, S. V. Sirak1, E.G. Skurikhin7, A. A. Sletov1, F. Witte10, G. Varga8, O. V. Vladimirova1, M.A. Vukovic2, D. Widera5
In this review poster, we summarize current knowledge on the oral neural crest-derived stem cell populations (oNCSCs) and discuss their potential in regenerative periodontology as a part of regenerative dentistry.
|Better Cell-Based Assays for Anti-CTLA-4, Anti-PD-1/PD-L1, and Bispecific Immunotherapy Drug Studies|
Richard Somberg, Mei Cong, Pete Stecha, Natasha Karassina, Jim Hartnett, Zhi-Jie Jey Cheng, and Frank Fan
Here we report the development of a panel of robust reporter assays to measure the potencies for biologics in immunotherapy. These assays reflect mode of action and can serve as valuable tools in immunotherapy drug development and discovery.
|Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy |
Zhi-jie Jey Cheng, Pete Stecha, Jim Hartnett, Frank Fan, and Mei Cong
Jurkat T-cells stably expressing luciferase reporter driven by IL2 promoter or NFAT-RE, are used as effector cells. Tumor cell lines endogenously expressing cancer antigen are used as antigen presenting cells (APC). By co-cultivating the two cell lines in the presence of CD3 bispecific antibody, TCR/CD3 is activated in Jurkat effector cells. Luciferase activity is up regulated through IL-2 promoter or NFAT-RE activation.
|Reporter Bioassays to Assess Therapeutic Antibodies for Immunotherapy Programs|
Mei Cong, Zhi-Jie Jey Cheng, Pete Stecha, Jun Wang, Jamison Grailer, Natasha Karassina, Jim Hartnett, and Frank Fan
Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.
|<<|| 1 2 3 4 || >>|
|Showing Results 1 - 10 of 40||